Introduction
============

The rising prevalence of obesity is considered a major cause for disorders such as type 2 diabetes (DM2) and cardiovascular diseases \[[@B1],[@B2]\]. Type of body fat distribution seems to play a crucial role in the pathogenesis of obesity-related diseases. Due to its higher endocrine and metabolic activity compared to subcutaneous adipose tissue, visceral adipose tissue is regarded as a predictor of cardiometabolic risk factor levels \[[@B2]-[@B6]\]. Abdominal obesity is strongly correlated with visceral adipose tissue, clinically represented by the measurement of waist circumference (WC) \[[@B7]\]. A population-based cohort study of diabetes revealed that a larger waist circumference is associated with a higher risk of DM2, especially in women, whereas larger hip and thigh circumferences are clearly associated with a lower risk of diabetes \[[@B8]\].

The widespread lipid disorder in visceral obesity, insulin resistance and metabolic syndrome is atherogenic dyslipidemia, which is characterized by triad of elevated serum triglycerides (TG), low HDL-cholesterol (HDL-C) and small LDL-C particles \[[@B3]\]. Several studies showed favorable effects of visceral weight loss on serum TG in overweight subjects \[[@B4],[@B9],[@B10]\].

The question is whether the achieved weight loss alone is responsible for the reduction in blood pressure. Besides weight loss, mental stress reduction, dietary sodium restriction, and an increased intake of dietary flavanoids are suggested to reduce blood pressure \[[@B11]-[@B13]\]. Weight loss can be achieved by a conventional structured energy-restricted modified diet alone or in combination with meal replacements for weight control. Recent reports indicated that such meal replacements coupled with a low-calorie diet can offer an effective option for weight reduction and improvements in metabolic risk factors in overweight patients \[[@B14]-[@B16]\]. Therefore, aim of this prospective randomized study was to evaluate whether a diet with meal replacements (MR) can be as effective as a conventional energy-restricted modified diet (control diet, C) on weight loss, body composition and cardiometabolic risk profile in overweight women.

Methods
=======

Participants
------------

Overweight women were recruited from two outpatient centers for nutrition education in Frankfurt/M and Berlin, Germany. Women aged between 18 and 60 years, BMI between 27.0 and 34.9 kg/m^2^and with one of the following blood lipids were included into the study: total cholesterol (TC) ≥ 200 mg/dL, LDL-cholesterol (LDL-C) ≥ 175 mg/dL, HDL-C ≤ 50 mg/dL, TG 150-400 mg/dL. Exclusion criteria were lactose or protein intolerance, hypo- or hyperthyroidism, pharmacological treatment of diabetes, intake of vitamins or mineral supplements, anticoagulants, cardiac pacemaker and contraindications to exercise. One hundred and thirteen subjects were screened (Figure [1](#F1){ref-type="fig"}). The study was approved by the ethics committees of the Chamber of Physicians of the German federal states of Hessen and Berlin. Informed consent was obtained from each participant prior to study onset.

![**Trial profile**.](1743-7075-8-64-1){#F1}

Study design
------------

In a 12-week open-label, randomized, controlled intervention trial, subjects were randomly assigned to the MR or the C group, respectively, by a computer-generated identification number in order of recruitment. Blood samples, dietary records, clinical and biochemical data were collected at baseline and repeated 12 weeks after dietary intervention. Primary end point of the study was weight loss. The planned sample size of 44 subjects per group, excluding drop-out rate, was based on a power of 80% to detect a difference of at least 2.0 ± 3.0 kg (mean ± SD) between both groups at a level of significance of α = 0.05.

Both dietary intervention groups were instructed to follow an energy-restricted diet of approximately 1200 kcal/d. Three meals (breakfast, lunch, and dinner) were recommended. The food choice was based on vegetables, fruits, whole grain cereal and low-fat dairy products (1.5% fat). The MR group was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars (FormMed HealthCare AG, Frankfurt/M, Germany) and to prepare their own lunch. The energy per serving of the MR meal is shown in Table [1](#T1){ref-type="table"}. Each MR represented a balanced diet product for weight reduction according to article 14a of the dietary regulation issued by the German Federal Ministry of Food, Agriculture and Consumer Protection, based on Commission Directive 1996/8/EC of 26 February 1996. The C group was advised to follow a conventional energy-restricted modified diet with 15-20% of energy intake in the form of protein, 50-55% of energy intake in the form of carbohydrates and approximately 30% of energy intake in the form of fat according to previous studies \[[@B15],[@B17]\].

###### 

Daily dietary intake with meal replacements (per serving size)

                          Shake   Soup   Bar
  ----------------------- ------- ------ ------
  Energy (kcal)           205     200    218
  Protein (g)             19      21.9   17.2
  Carbohydrates (g)       16.9    12.9   27.0
  Fat (g)                 5.9     6.6    6.8
  Fatty acids                            
  SAFA (g)                2.6     0.9    2.2
  LA (g)                  1.0     3.1    2.2
  MUFA (g)                1.1     1.35   2.4
  Dietary fibre (g)       2.4     1.5    3.1
                                         
  **Minerals**                           
  Sodium (mg)             180     900    183
  Potassium (mg)          510     605    539
  Magnesium (mg)          200     61     82
  Calcium (mg)            525     300    329
  Phosphate (mg)          357     208    279
  Iron (mg)               7.5     4.9    8
  Zinc (mg)               5.0     3.0    7.4
  Manganese (mg)          0.6     0.4    1.5
  Copper (mg)             0.7     0.4    1.0
  Iodine (μg)             75      41     75
  Selenium (μg)           36      16.5   27
                                         
  **Vitamins**                           
  Vitamin A (μg)          400     210    600
  Vitamin B1 (mg)         0.7     0.3    0.8
  Vitamin B2 (mg)         1.2     0.5    0.9
  Vitamin B6 (mg)         1.0     0.5    1.1
  Vitamin B12 (μg)        1.5     0.4    1.7
  Vitamin C (mg)          45      13.5   34
  Vitamin D (μg)          2.5     1.5    2.9
  Vitamin E (mg)          10      3.0    11.5
  Biotin (μg)             75      4.5    86
  Folic acid (μg)         150     60     115
  Nicotinic acid (mg)     12      5.4    10
  Pantothenic acid (mg)   3.0     0.9    5.7

During a 12-week intervention period all participants attended ten group training sessions (eight to ten women per class) and four face-to-face visits for nutrition education. All participants received instruction manuals that included a sample meal plan, recipes and information regarding physical activity. Group training lasted one hour per session. Group training sessions were held separately for each group by a nutrition advisor. Topics of the structured sessions included practical knowledge of food, portion sizes and meal frequency with the aim of changing dietary behavior and lifestyle. The average duration of the monthly face-to-face visits was 25 minutes (range 10-40 minutes).

At baseline women were instructed on food selection, portion size estimation and accurate recording of dietary intakes. Three-day food records were documented at baseline and after the 12-week intervention. Dietary records were reviewed with each study participant and analyzed using PRODI 5.3 software (WVG, Stuttgart, Germany).

Body weight (kg) and height (cm) were measured. WC, HC and thigh circumference was determined via flexible tape. The goal to achieve \> 5% weight loss was a targeted value. Body fat mass (BFM), body fat (%), body cell mass (BCM), and lean body mass (LBM) were determined by bioelectrical impedance analysis (BIA) with biaform^®^software version 2.2 under standardized conditions \[[@B17]\]. Blood pressure (BP) was measured under standardized conditions after a 10 min. resting period. Anthropometric measurements and venous blood sampling were performed in the morning after an overnight fasting period of at least 12 h. Due to analysis of serum cortisol, blood samples were taken at 9:00 a.m. At baseline and after the 12-week dietary intervention, 24-hour urines were collected.

Laboratory methods
------------------

Analyses of serum glucose (hexokinase method), uric acid (uricase-PAP method), gamma-glutamyltransferase (kinetic color test IFCC), total cholesterol (TC) (CHOD-PAP method), LDL-C and HDL-C (enzymatic color test), TG (GPO-PAP method) on Olympus 600 analyzer, homocysteine, folic acid and cortisol (chemiluminiscence method) on ADVIAR Centaur analyzer and glycated hemoglobin (HbA1c) (HPLC) on Biorad Variant II analyzer were conducted by the medical laboratory Potsdam, Germany.

Determination of the total antioxidative capacity (TAC) was performed by the reaction of antioxidants in the sample with a defined amount of exogenously provided hydrogen peroxide (H~2~O~2~). The antioxidants in the sample eliminate a certain amount of the provided hydrogen peroxide. The residual H~2~O~2~is determined photometrically by an enzymatic reaction which involves the conversion of TMB to a colored product.

Analysis of 24 h urinary sodium excretion (ion sensitive electrode (ISE)) was performed at the laboratory of Medical Nutrition Science, Department of Urology, University of Bonn, Germany.

Laboratory quality certification was available for each parameter except for homocysteine, folic acid and TAC.

Statistical methods
-------------------

Statistical comparisons between groups were performed using the nonparametric Mann-Whitney U test for unpaired data. Pre-post intervention changes were analyzed via non-parametric Wilcoxon test. All statistical tests were two-sided. Differences were considered significant at p \< 0.05. Data are reported as mean ± standard deviation (SD). ANCOVA including use of weight change and age as covariates was used to control for the potential confounder of systolic BP. Data analysis was performed based on the per protocol population and by using SPSS^®^for Windows (version 19.0).

Results
=======

Participants
------------

A total of 105 overweight women were randomized, of whom 87 were eligible for per protocol (PP) analysis (Figure [1](#F1){ref-type="fig"}). Twelve women discontinued the study: one due to adverse effects (diarrhea) in the MR group and 11 for personal reasons (four women in the MR and seven women in the C group). Additionally, six women had to be excluded from analysis due to protocol violations. Meal replacements were well tolerated by the patients.

No differences were observed at baseline between both groups regarding anthropometric, clinical and biochemical parameters. Fifty-nine women (67.8%) had obesity stage I (Table [2](#T2){ref-type="table"}). The ratio of obesity stage I (30.0-34.9 kg/m^2^) to preobesity (27.0-29.9 kg/m^2^) was approximately 2:1 in both groups. Abdominal adipose tissue distribution type (WC \> 88 cm) did not differ between the MR and the C group. Systolic blood pressure (130/80 mmHg) was slightly above the cutoff in the MR group \[[@B3]\].

###### 

Baseline characteristics of overweight women in the meal replacement (MR) and control group (C), respectively

  ---------------------------------------------------------------------
                               MR\            C\             MR vs C\
                               (n = 43)\      (n = 44)\      P
                               Mean ± SD      Mean ± SD      
  ---------------------------- -------------- -------------- ----------
  Age (years)                  49.8 ± 11.7    49.6 ± 11.0    0.776^a^

                                                             

  Weight (kg)                  83.9 ± 8.8     84.1 ± 8.3     0.946^a^

                                                             

  Height (cm)                  163.8 ± 5.9    164.0 ± 5.8    0.909^a^

                                                             

  BMI (kg/m^2^)                31.2 ± 2.3     31.2 ± 2.1     0.912^a^

  BMI 27.0 - 29.9 kg/m^2^(n)   14 (32.6%)     14 (31.8%)     0.941^b^

  BMI 30.0 - 34.9 kg/m^2^(n)   29 (67.4%)     30 (68.2%)     0.941^b^

                                                             

  WC (cm)                      93.9 ± 7.2     94.9 ± 6.1     0.491^a^

  WC 80 - 88 cm (n)            12 (27.9%)     7 (15.9%)      0.176^b^

  WC \> 88 cm (n)              31 (72.1%)     37 (84.1%)     0.176^b^

                                                             

  BP systolic (mmHg)           131.2 ± 17.4   128.0 ± 19.7   0.185^a^

  BP systolic ≥ 130 mmHg (n)   27 (62.8%)     22 (50.0%)     0.229^b^

                                                             

  BP diastolic (mmHg)          80.8 ± 9.6     79.8 ± 9.0     0.321^a^

  BP diastolic ≥ 85 mmHg (n)   16 (37.2%)     11 (25.0%)     0.218^b^

                                                             

  Heart rate (1/min)           76.6 ± 10.6    77.8 ± 10.8    0.792^a^

  Heart rate \> 70/min (n)     33 (76.7%)     34 (77.3%)     0.953^b^

                                                             

  Oral contraceptives (n)      5 (11.6%)      3 (6.8%)       0.438^b^

                                                             

  Smokers (n)                  7 (16.3%)      9 (20.5%)      0.615^b^
  ---------------------------------------------------------------------

abbreviations used: BMI, body mass index; BP, blood pressure; WC, waist circumference

^a^Mann-Whitney-U-test

^b^Chi^2^-Test

Anthropometric and clinical characteristics
-------------------------------------------

Dietary intervention resulted in a significant weight loss in both groups, without significant difference between the MR and the C group (Table [3](#T3){ref-type="table"}). However, relative weight loss in the MR group was higher compared to the C group (p = 0.048). Moreover, the rate of responder (\>5% weight loss) was higher in the MR group (33 women, 77%) versus the C group (22 women, 50%) after the 12-week dietary intervention (p = 0.010) (Table [4](#T4){ref-type="table"}). While women with WC ≤ 88 cm (21.8% in both groups) lost significantly more weight in the MR group (MR: - 5.98 ± 2.28 kg, C: - 0.96 ± 2.29 kg; p = 0.002), no significant difference in weight change was observed in women with WC \> 88 cm (MR: -5.98 ± 3.04 kg, C: - 5.57 ± 3.25 kg; p = 0.506).

###### 

Anthropometric and clinical characteristics in overweight women at baseline and after dietary intervention

  ------------------------------------------------------------------------------------------------------------------------------------------
                                MR (n = 43)\   C (n = 44)\      MR vs C                                                           
                                Mean ± SD      Mean ± SD                                                                          
  ----------------------------- -------------- ---------------- ---------------- -------------- ---------------- ---------------- ----------
                                **Baseline**   **Week 12**      **Difference**   **Baseline**   **Week 12**      **Difference**   **P^a^**

                                                                                                                                  

  Weight (kg)                   83.9 ± 8.8     78.0 ± 9.2\*\*   -5.98 ± 2.82     84.1 ± 8.3     79.3 ± 7.3\*\*   -4.84 ± 3.54     0.075

                                                                                                                                  

  Relative weight loss (%)      100 ± 0        92.8 ± 3.3\*\*   -7.19 ± 3.25     100 ± 0        94.4 ± 4\*\*     -5.60 ± 4.02     0.048

                                                                                                                                  

  BMI (kg/m^2^)                 31.2 ± 2.3     29.0 ± 2.6\*\*   -2.24 ± 1.02     31.2 ± 2.1     29.4 ± 1.9\*\*   -1.79 ± 1.31     0.075

                                                                                                                                  

  WC (cm)                       93.9 ± 7.2     87.4 ± 7.6\*\*   -6.55 ± 3.91     94.9 ± 6.1     89.6 ± 6.3\*\*   -5.30 4.27       0.094

                                                                                                                                  

  WHtR                          0.574\         0.534\           0.040\           0.579\         0.547\           0.032\           0.092
                                ± 0.043        ± 0.047\*\*      ± 0.024          ± 0.040        ± 0.045\*\*      ± 0.026          

                                                                                                                                  

  HC (cm)^b^                    114.2 ± 6.4\   108.5 ± 6.0      -5.71 ± 2.34     114.3 ± 6.0\   109.4 ± 6.5      -4.93 ± 3.45     0.565
                                (n = 26)                                         (n = 28)                                         

                                                                                                                                  

  WHR^b^                        0.83 ± 0.06\   0.82 ± 0.05      -0.01 ± 0.03     0.84 ± 0.05\   0.84 ± 0.06      0.00 ± 0.03      0.350
                                (n = 26)                                         (n = 28)                                         

                                                                                                                                  

  Thigh circumference (cm)^b^   64.1 ± 5.0     60.8 ± 5.1       -3.33 ± 2.10     64.1 ± 4.6     61.5 ± 5.0       -2.59 ± 2.35     0.158

                                (n = 35)                                         (n = 38)                                         

                                                                                                                                  

  BFM (kg)                      36.1 ± 6.3     31.4 ± 6.4\*\*   -4.69 ± 2.31     36.6 ± 6.0     32.6 ± 5,2\*\*   -3.98 ± 2.53     0.144

                                                                                                                                  

  Body fat (%)                  42.7 ± 3.8     39.9 ± 4.3\*\*   -2.79 ± 1.79     43.3 ± 3.6     41.0 ± 3.6\*     -2.33 ± 1.51     0.191

                                                                                                                                  

  BCM (kg)                      25.7 ± 2.5     24.8 ± 2.6\*\*   -0.93 ± 0.80     25.7 ± 2.3     24.7 ± 2.0\*\*   -0.98 ± 0.98     0.760

                                                                                                                                  

  BCM (%)                       30.8 ± 2.9     32.0 ± 3.1\*\*   1.19 ± 1.24      30.7 ± 3.0     31.3 ± 2.9\*     0.62 ± 1.17      0.054

                                                                                                                                  

  LBM (kg)                      48.1 ± 3.8     46.8 ± 3.9\*\*   -1.30 ± 1.40     47.7 ± 3.8     46.9 ± 3.3\*\*   -0.77 ± 1.46     0.058

                                                                                                                                  

  LBM (%)                       57.6 ± 3.8     60.4 ± 4.3\*\*   2.81 ± 2.22      56.9 ± 3.7     59.4 ± 3.7\*\*   2.45 ± 1.93      0.445

                                                                                                                                  

  BP systolic (mmHg)            131.2          119.8            -11.4            128.0          119.5            -8.5             0.148

                                ± 17.4         ± 12.8\*\*       ± 18.8           ± 19.7         ± 13.8\*         ± 23.5           

                                                                                                                                  

  BP diastolic (mmHg)           80.8 ± 9.6     77.2 ± 8.6\*     -3.6 ± 11.7      79.8 ± 9.0     75.5 ± 8.3\*     -4.4 ± 11.7      0.914

                                                                                                                                  

  Heart rate (1/min)^b^         77.0 ± 10.3\   75.8 ± 9.9       -1.2 ± 8.0       77.8 ± 10.8    75.8 ± 11.5      -2.0 ± 8.9       0.983
                                (n = 42)                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------

abbreviations used: BCM, body cell mass; BFM, body fat mass; BMI, body mass index; BP, blood pressure; C, control group; HC, hip circumference; LBM, lean body mass; MR, meal replacement group; WC, waist circumference; WHR, Waist-to-hip ratio; WHtR, Waist-to-height ratio

\*p \< 0.05; \*\* p \< 0.001; Wilcoxon-test within groups

^a^p-value: Mann-Whitney-U-test

^b^data not available for all women

###### 

Change in the cardiometabolic risk profile in overweight women after dietary intervention

  ------------------------------------------------------------------------------------------------------------------
                          MR (n = 43)\   C (n = 44)\   MR vs C                                            
                          n (%)          n (%)                                                            
  ----------------------- -------------- ------------- ---------- -------------- ------------- ---------- ----------
                          **Baseline**   **Week 12**   **P^a^**   **Baseline**   **Week 12**   **P^a^**   **P^b^**

                                                                                                          

  Weight reduction\       \-             33\           \-         \-             22\           \-         0.010
  \> 5%                                  (76.7%)                                 (50.0%)                  

                                                                                                          

  WC \> 88 cm             31\            19\           0.009      37\            24\           0.003      0.429
                          (72.9%)        (44.2%)                  (84.1%)        (54.5%)                  

                                                                                                          

  BP systolic\            28\            15\           0.005      20\            12\           0.076      0.263
  ≥ 130 mmHg              (65.1%)        (34.9%)                  (45.5%)        (27.3%)                  

                                                                                                          

  BP diastolic\           13\            9\            0.323      6\             6\            1.000      0.229
  ≥ 85 mmHg               (30.2%)        (20.9%)                  (13.6%)        (13.6%)                  

                                                                                                          

  BP ≥ 130/85 mmHg        12\            5\            0.058      6\             5\            0.747      0.439
                          (27.9%)        (11.6%)                  (13.6%)        (11.4%)                  

                                                                                                          

  TG ≥ 150 mg/dl          14\            16\           0.651      15\            13\           0.647      0.897
                          (41.2%)^c^     (47.1%)^c^               (44.1%)^c^     (38.2%)^c^               

                                                                                                          

  HDL-C \< 50 mg/dl       11\            12\           0.808      8\             11\           0.437      0.851
                          (32.4%)^c^     (35.3%)^c^               (23.5%)^c^     (32.4%)^c^               

                                                                                                          

  Fasting glucose\        2\             2\            1.000      3\             1\            0.306      0.906
  ≥ 110 mg/dl             (5.9%)^c^      (5.9%)^c^                (8.8%)^c^      (2.9%)^c^                

                                                                                                          

  Hypertriglyceridemic\   12\            7\            0.194      14\            7\            0.080      0.984
  waist^d^                (35.3%)^c^     (20.6%)^c^               (41.2%)^c^     (20.6)^c^                

                                                                                                          

  Atherogenic\            6\             7\            0.763      4\             3\            0.694      0.490
  dyslipidemia^e^         (17.6%)^c^     (20.6%)^c^               (11.8%)^c^     (8.8%)^c^                
  ------------------------------------------------------------------------------------------------------------------

abbreviations used: BP, blood pressure; C, control group; HDL-C, HDL cholesterol; MR, meal replacement group; WC, waist circumference

^a^p-value: chi-square-test within groups

^b^p-value: chi-square-test in contingency tables

^c^biochemical analysis with the same method (n = 34)

^d^hypertriglyceridemic waist, i.e. WC \> 88 cm and TG ≥ 150 mg/dL \[[@B18]\]

^e^atherogenic dyslipidemia, i.e. triad of elevated triglycerides, low HDL-C, and small LDL-C particles \[[@B3]\]

Dietary intervention significantly reduced mean BMI from obesity stage I to preobesity in both groups (Table [3](#T3){ref-type="table"}). Correspondingly, WC and waist-to-height ratio (WHtR) significantly decreased to a similar extent. After the 12-week dietary intervention, mean WC was below the cutoff of 88 cm only in the MR group \[[@B3]\]. Within group analysis revealed a significant reduction in BFM, body fat (%), BCM, and LBM in both groups. After the 12-week dietary intervention, mean systolic and diastolic BP were within the normal range.

Clinical chemistry and biochemical characteristics
--------------------------------------------------

After the 12-week dietary intervention TC, LDL-C but also HDL-C significantly decreased in both groups, without significant differences between the groups (Table [5](#T5){ref-type="table"}). No change was observed in serum TG, glucose and uric acid within and between groups during intervention. Serum homocysteine concentration increased significantly only in the C group, but this was without clinical relevance. Serum folic acid concentration increased significantly only in the MR group. Serum cortisol concentration and TAC remained unchanged during the intervention period. GGT activity decreased significantly in both groups to a similar extent.

###### 

Clinical chemistry and biochemical characteristics in overweight women at baseline and after dietary intervention

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            **MR (n = 34) ^a^Mean ± SD**   C (n = 34) ^a^Mean ± SD   MR vs C                                                               
  ------------------------- ------------------------------ ------------------------- ----------------- --------------- ---------------- ------------------ ----------
                            **Baseline**                   **Week 12**               **Difference**    **Baseline**    **Week 12**      **Difference**     **P^b^**

                                                                                                                                                           

  Glucose (mg/dL)           91.8 ± 13.7                    92.4 ± 10.9               0.63 ± 10.94      90.7 ± 14.3     88.1 ± 13.1      -2.66 ± 10.74      0.315

                                                                                                                                                           

  HbA1c (%)                 5.54 ± 0.63                    5.49 ± 0.47               -0.05 ± 0.64      5.63 ± 0.51     5.46 ± 0.48      -0.16 ± 0.61       0.201

                                                                                                                                                           

  TC (mg/dL)                241.2 ± 53.1                   224.4 ± 53.2\*            -16.7 ± 33.7      241.5 ± 34.3    230.3 ± 40.9\*   -11.2 ± 25.9       0.556

                                                                                                                                                           

  HDL-C (mg/dL)             59.1 ± 16.1                    55.3 ± 14.1\*\*           -3.7 ± 6.2        59.2 ± 11.5     55.7 ± 10.9\*    -3.5 ± 5.2         0.864

                                                                                                                                                           

  LDL-C (mg/dL)             157.0 ± 39.7                   144.0 ± 38.4\*\*          -13.0 ± 18.2      161.4 ± 24.2    152.3 ± 30.8\*   -9.1 ± 18.7        0.647

                                                                                                                                                           

  TG (mg/dL)                186.4 ± 145.6                  161.1 ± 108.0             -25.3 ± 110.4     152.5 ± 83.8    141.6 ± 66.1     -10.9 ± 52.9       0.861

                                                                                                                                                           

  TG/HDL-C                  3.59 ± 3.55                    3.19 ± 2.49               -0.40 ± 2.44      2.71 ± 1.66     2.62 ± 1.37      -0.09 ± 0.96       0.880

                                                                                                                                                           

  LDL-C/HLD-C               2.81 ± 0.86                    2.73 ± 0.86               -0.08 ± 0.33      2.81 ± 0.63     2.79 ± 0.68      -0.02 ± 0.33       0.539

                                                                                                                                                           

  GGT (U/L)                 33.5 ± 28.8                    27.8 ± 20.1               -5.72 ± 12.91\*   27.9 ± 13.3     24.0 ± 10.6      -3.85 ± 4.92\*\*   0.759

                                                                                                                                                           

  Uric acid (mg/dL)         4.82 ± 1.18                    4.59 ± 0.94               -0.23 ± 0.70      4.86 ± 1.01     4.75 ± 0.97      0.11 ± 0.66        0.384

                                                                                                                                                           

  Homocysteine\             11.7 ± 4.1                     11.0 ± 2.7                -0.63 ± 2.66      10.3 ± 2.0      11.7 ± 2.7\*     1.36 ± 2.65        0.007
  (μmol/L)                                                                                                                                                 

                                                                                                                                                           

  Folic acid (μg/L)         10.6 ± 4.9                     15.2 ± 5.8\*\*            4.62 ± 5.74       11.1 ± 4.3      12.3 ± 7.2       1.17 ± 6.28        0.005

                                                                                                                                                           

  GFR (mL/min/1.73 m^2^)    73.6 ± 12.0                    73.3 ± 12.1               -0.24 ± 6.50      74.8 ± 8.9      72.5 ± 8.8       -2.27 ± 6.10       0.202

                                                                                                                                                           

  TAC (μmol/L)              266.2 ± 30.8                   276.6 ± 38.4              10.4 ± 45.6       280.9 ± 43.0    282.2 ± 45.7     1.3 ± 48.5         0.210

                                                                                                                                                           

  Cortisol (nmol/L)         424.3 ± 142.5                  532.1 ± 179.6             107.8 ± 145.6     387.2 ± 164.6   477.4 ± 140.9    90.2 ± 176.0       0.826

                                                                                                                                                           

  TAC/Cortisol (10^3^)      0.70 ± 0.27                    0.58 ± 0.20               -0.12 ± 0.27      0.89 ± 0.49     0.65 ± 0.25      -0.24 ± 0.41       0.498

                                                                                                                                                           

  U-sodium (mmol/24 h)^c^   162.2 ± 64.5                   158.2 ± 94,1              -4.0 ± 118.0      158.3 ± 68.1    170.8 ± 81.2     12.5 ± 82.9        0.283
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

abbreviations used: GFR, glomerular filtration rate; GGT, gamma-glutamyltransferase; HbA1c, glycated haemoglobin; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; TAC, total antioxidative capacity; TC, total cholesterol; TG, triglycerides; U-sodium, urinary sodium

^a^biochemical measurements with the same method

^b^p-value: Mann-Whitney-U-test; Wilcoxon-test within groups: \*p \< 0.05; \*\*p \< 0.001

^c^n = 26 in the MR group and n = 28 in the C group

Cardiometabolic risk profile
----------------------------

Table [4](#T4){ref-type="table"} reflects results related to the cardiometabolic risk profile. The total number of subjects classified with atherogenic dyslipidemia \[[@B3]\] did not reduce significantly during the study. After the 12-week dietary intervention hypertriglyceridemic waist phenotype, i.e. WC \> 88 cm and TG ≥ 150 mg/dL \[[@B18]\], decreased by 42% in the MR group and by 50% in the C group.

Dietary intake
--------------

At baseline, the reported energy intake was similar in both groups (MR: 1574 ± 408 kcal/d; C: 1683 ± 414 kcal/d). After the 12-week intervention energy intake was significantly reduced within each group but not between both groups (MR: 1268 ± 306 kcal/d; C: 1406 ± 392 kcal/d). The calculated energy expenditure estimated with Harris-Benedict equation \[[@B19]\] at a physical activity level (PAL) of 1.6 differed from these data in both groups at baseline (MR group: 2356 ± 191 kcal/d C group: 2378 ± 163 kcal/d) and therefore suggested underreporting. Dietary sodium intake was estimated from 24 h urinary sodium excretion.

Discussion
==========

Our results indicate that both weight loss strategies are effective treatment options for overweight women. The goal to achieve a weight loss of more than 5% (4.2 kg of mean body weight at baseline) after 12 weeks was exceeded by at least 1.8 kg in the MR group but only by 0.6 kg in the C group, which is reflected in the significantly increased responder rate of the MR group. These results can be attributed to the preference for convenience foods \[[@B20]\] The weight loss of approximately 5% achieved in both groups is similar to that reported for preobesity and obesity stage I \[[@B14]-[@B16],[@B21]\]. It has been reported that especially time and structure of the nutritional education play an important role in achieving high compliance \[[@B14]\]. Moreover, regular education to achieve an increase in physical activity is necessary, especially for maintaining the body weight \[[@B22]\].

For the evaluation of cardiometabolic risk not only body weight is important. The role of the body fat distribution phenotype has been shown to be even more prominent than that of BMI \[[@B23]\]. Compared to visceral fat, a high proportion of subcutaneous fatty tissue is accompanied by a lower cardiometabolic risk. Therefore, reduction in WC is considered to be more essential than loss of body weight alone, especially in DM2 \[[@B24]\]. Studies have shown that WHtR is the best indicator of cardiovascular risk in different measures of abdominal obesity and that it can be used to assess body composition \[[@B25]\]. In the present study, the significant decrease in WC and WHtR in both groups during dietary intervention suggests that the body fat distribution phenotype has changed. A general cutoff of 0.5 has been suggested for WHtR \[[@B26]\]. However, this value was not achieved in our study population.

A strong association has been demonstrated between WC and plasma TG \[[@B27]\]. After the 12-week dietary intervention a decrease in WC by 6.6 cm in the MR group and by 5.5 cm in the C group was achieved. Surprisingly, in our study no significant reduction in fasting serum TG and glucose was observed in the present trial.

In our study, a similar reduction of TC and LDL-C was found in both groups, which can be attributed to energy restriction and the resulting weight loss. Although the significant decrease in HDL-C is remarkable, mean HDL-C at baseline and after the 12-week dietary intervention was above the cutoff of 50 mg/dL. It is notable that the number of women with a HDL-C below 50 mg/dL, TG above 150 mg/dL and atherogenic dyslipidemia, respectively, did not change in both groups. Although several studies found that weight reduction in overweight and obese subjects favorably modifies atherogenic dyslipidemia \[[@B28],[@B29]\], we were unable to confirm these findings. One reason could be the fatty acid composition of the dietary intervention with an insufficient proportion of MUFA and especially long-chain n-3 polyunsaturated fatty acids (n-3 LC PUFA).

Moreover, the 12-week dietary intervention resulted in a significant and similar improvement of systolic and diastolic BP in both groups. However, the number of women with systolic BP ≥ 130 mmHg decreased significantly only in the MR group and the number of women with a BP of 130/85 mmHg tended to decrease after 12 weeks.

In the present study, body weight loss resulted in a significant reduction in systolic BP in the study population (p = 0.002) (Table [6](#T6){ref-type="table"}). This effect depended on the body weight at baseline. The higher the initial body weight, the higher was the reduction in systolic BP and diastolic BP. One kg of weight loss resulted in a reduction of systolic and diastolic BP by 2.0 and 1.1 mmHg, respectively. The effect of weight loss on systolic BP was more pronounced in the C group and amounted to 3.5 mmHg per kg body weight (p = 0.001) as compared to 1.0 mmHg per kg body weight in the MR group (p = 0.480). Diastolic BP was similar with 1.7 mmHg per kg body weight in the C group (p \< 0.001), and 0.4 mmHg in the MR group (p = 0.545).

###### 

Systolic blood pressure depending on body weight, sodium intake and serum cortisol (age-adjusted)

  Body weight                                      
  -------------------- ---------------- ---------- -------
  **Group**            **Difference**   **RC B**   **P**
  C (n = 34)           -5.0 ± 3.5       3.516      0.001
  MR (n = 33)          -6.6 ± 2.6       1.028      0.480
                                                   
  **Urinary sodium**                               
                                                   
  Group                Difference       RC B       P
  C (n = 34)           3.5 ± 70.6       -0.051     0.383
  MR (n = 33)          -29.7 ± 86.7     0.068      0.106
                                                   
  **Serum cortisol**                               
                                                   
  Group                Difference       RC B       P
  C (n = 34)           95.2 ± 164.6     0.041      0.105
  MR (n = 33)          118.7 ± 159.1    -0.015     0.515

abbreviations used: C, control group; MR, meal replacement group; RC B, regression coefficient B

Apart from the influence of weight loss on the systolic blood pressure, dietary sodium intake, estimated from 24 h urinary sodium excretion, seemed to exert different effects on both groups. No convincing association was found between systolic BP and serum cortisol and between systolic BP and sodium intake (Table [6](#T6){ref-type="table"}). Body cell mass (BCM) and lean body mass (LBM) decreased in both groups, while the percentage of BCM of body weight increased more in the MR group than in the C group. The higher increase in the difference in absolute BCM in the MR group versus C group resulted in a reduction in systolic BP, whereas BCM affected systolic BP in the C group only via weight reduction (Table [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}). The different changes in body composition and the different impact of body weight are reflected in non-BCM and BCM. The result from the C group shows that non-BCM is the dominant factor for systolic BP reduction, while BCM was found to be the major factor in the MR group. The systolic BP decreased to a similar extent in both groups despite different influencing variables.

###### 

Systolic blood pressure depending on BCM and non-BCM (age-adjusted)

  -------------------------------------------------
  Group   P\       dnon-BCM        dBCM
          ANCOVA                   
  ------- -------- --------------- ----------------
  Total   0.005    2.257\          0.135\
                   (0.7 - 3.8)\    (-4.8 - 5.1)\
                   0.004           0.957

                                   

  C       0.013    2.765\          3.226\
                   (0.5 - 5.0)\    (-4.0 - 10.4)\
                   0.018           0.372

                                   

  MR      0.218    1.231\          -4.689\
                   (-1.0 - 3.5)\   (-11.9 - 2.6)\
                   0.278           0.198
  -------------------------------------------------

abbreviations used: BCM, body cell mass; C, control group; d, difference; MR, meal replacement group

GGT is the enzyme responsible for initiating extracellular catabolism of glutathione \[[@B30]\]. Increased GGT activity may be a response to oxidative stress, which can increase the transport of glutathione precursors into cells \[[@B30],[@B31]\] and is involved in the generation of reactive oxygen species \[[@B31]\]. Therefore, it has been suggested that higher GGT levels are associated with an increased risk for the development of hypertension \[[@B32]\]. In our study, we found a significant reduction in GGT activity in both groups.

Evidence suggests that reactive oxygen species are fundamentally involved in hyperhomocysteinemia, which, together with a low folate status, is a major risk factor for atherosclerosis \[[@B33]\]. In the present study, a significant higher serum homocysteine was found after the 12-week dietary intervention in the C group when compared to the MR group. This result was probably due to a better folate status through increased intake with the MR, as demonstrated by the significant increase in serum folic acid in the MR group.

In conclusion, both groups exhibited an effective weight loss. Compliance was higher in the MR group than in the C group as demonstrated by the higher responder rate in the MR (77%) than in the C group (50%). Cardiometabolic risk was positively affected mainly through the decrease in BP, TC and LDL-C, whereas other risk factors were not affected by the 12-week dietary intervention. Systolic BP decreased to a similar extent in both groups despite different influencing variables. The significant lower serum homocysteine and higher folic acid after the 12-week dietary intervention in the MR group was probably due to a better folate status through increased intake with the MR. Cardiometabolic risk profile improved only partly in both groups.
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